- Home
- ORKA vs MANE Comparison
ORKA vs MANE Comparison
Compare ORKA & MANE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ORKA | MANE |
|---|---|---|
| Founded | 2004 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.3B |
| IPO Year | N/A | 2026 |
Fundamental Metrics
Financial Performance| Metric | ORKA | MANE |
|---|---|---|
| Price | $32.18 | $43.85 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 10 | 0 |
| Target Price | ★ $52.70 | N/A |
| AVG Volume (30 Days) | 454.9K | ★ 735.6K |
| Earning Date | 03-05-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.49 | $32.00 |
| 52 Week High | $36.51 | $45.78 |
Technical Indicators
Market Signals| Indicator | ORKA | MANE |
|---|---|---|
| Relative Strength Index (RSI) | 54.14 | N/A |
| Support Level | $31.00 | N/A |
| Resistance Level | $33.89 | N/A |
| Average True Range (ATR) | 1.96 | 0.00 |
| MACD | -0.28 | 0.00 |
| Stochastic Oscillator | 46.78 | 0.00 |
Price Performance
Historical ComparisonAbout ORKA Oruka Therapeutics Inc.
Oruka Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. The company's co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. These programs each bind their respective targets at high affinity and incorporate half-life extension technology to increase exposure and decreasing dosing frequency.